Lexeo Therapeutics, Inc. Common Stock
LXEO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $654 | $1,657 |
| % Growth | – | -100% | -60.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $654 | $1,657 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $74,091 | $53,130 | $49,162 | $45,121 |
| G&A Expenses | $31,675 | $15,383 | $12,001 | $7,173 |
| SG&A Expenses | $31,675 | $15,383 | $12,001 | $7,173 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $105,766 | $68,513 | $61,163 | $52,294 |
| Operating Income | -$105,766 | -$68,513 | -$60,509 | -$50,637 |
| % Margin | – | – | -9,252.1% | -3,055.9% |
| Other Income/Exp. Net | $7,433 | $2,119 | $1,232 | $15 |
| Pre-Tax Income | -$98,333 | -$66,394 | -$59,277 | -$50,622 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$98,333 | -$66,394 | -$59,277 | -$50,622 |
| % Margin | – | – | -9,063.8% | -3,055% |
| EPS | -3.09 | -2.49 | -2.36 | -2.01 |
| % Growth | -24.1% | -5.5% | -17.4% | – |
| EPS Diluted | -3.09 | -2.49 | -2.4 | -2.01 |
| Weighted Avg Shares Out | 31,787 | 26,646 | 25,169 | 25,169 |
| Weighted Avg Shares Out Dil | 31,787 | 26,646 | 25,169 | 25,169 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,556 | $2,867 | $1,325 | $15 |
| Interest Expense | $114 | $205 | $91 | $0 |
| Depreciation & Amortization | $2,002 | $1,843 | $1,145 | $13 |
| EBITDA | -$96,194 | -$64,346 | -$58,041 | -$50,609 |
| % Margin | – | – | -8,874.8% | -3,054.3% |